Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KITE-753 versus axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
NL-OMON61376Phase 3Not yet recruiting
- Sponsor
- Kite Pharma
- Start
- Sep 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of KITE-753, axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
KITE-753axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON61376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61376.